James J. Mulay - 09 Jan 2026 Form 4 Insider Report for CG Oncology, Inc. (CGON)

Role
Director
Signature
/s/ Joshua F. Patterson, Attorney-in-Fact for James J. Mulay
Issuer symbol
CGON
Transactions as of
09 Jan 2026
Net transactions value
-$450,284
Form type
4
Filing time
13 Jan 2026, 16:15:07 UTC
Previous filing
10 Oct 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mulay James Director C/O CG ONCOLOGY, INC., 400 SPECTRUM CENTER DRIVE, SUITE 2040, IRVINE /s/ Joshua F. Patterson, Attorney-in-Fact for James J. Mulay 13 Jan 2026 0001684531

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGON Common Stock Options Exercise $2,433 +654 $3.72 654 09 Jan 2026 Direct
transaction CGON Common Stock Sale $28,881 -654 -100% $44.16 0 09 Jan 2026 Direct F1
transaction CGON Common Stock Options Exercise $132,082 +10,491 $12.59 10,491 09 Jan 2026 Direct
transaction CGON Common Stock Sale $555,918 -10,491 -100% $52.99 0 09 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGON Director Stock Option (right to buy) Options Exercise $0 -654 -33% $0.000000 1,308 09 Jan 2026 Common Stock 654 $3.72 Direct F2
transaction CGON Director Stock Option (right to buy) Options Exercise $0 -10,491 -67% $0.000000 5,240 09 Jan 2026 Common Stock 10,491 $12.59 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
F2 The stock option vests in 36 substantially equal monthly installments beginning on July 14, 2023.
F3 The stock option vests in 36 substantially equal monthly installments beginning on January 13, 2024.